They Just Don't Get...
Health Care: Drugs
EntreMed Inc. (ENMD: NASDAQ)
$2.03 0.07 | 3.57%
06/04/12 - 03:59 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.97 | 0.58 | 0.98 |
| Price to Sales (TTM) | 22.72 | 4.62 | 1.42 |
| Price to Book (MRQ) | 0.00 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | -47.41 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -8.10 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -11.60 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -47.40 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -23.18 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -72.59 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.20 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 1.20 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | n.a. | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 96.70 | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -555.99 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -2.32 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -37.50 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -65.00 | 2.20 | 2.50 |
| Return on Investment (TTM) | -185.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -102.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 277,270.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -642,282.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.20 | 0.40 | 0.40 |
Portfolios with ENMD
- Portfolio NameUser Type
- Contributor6 Drug Stocks Unworthy of B...
- UserBeaver
- Contributor10 Stocks Under $5 Outperfo...
- ContributorStocks Under $5 at Risk of ...
- UserDorkingLad Portfolio 1
- Usersmallbiz
- Usersteves #1
- UserThe Investment Psychologist...
- Userdrweik Portfolio 1
- UserJake's Portfolio 1
Latest ENMD Headlines from TheStreet
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- 10 Stocks Under $5 Outperforming in 2012 01.31.12 | 05:01 am
- Stocks Under $5 at Risk of Bankruptcy 06.08.11 | 06:06 am
- Biotech Sector Weekly Rewind 11.20.10 | 08:11 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Sprint Nextel, Palm: Early Volume Plays 04.19.10 | 07:04 am
- ThermoGenesis, Power-One: Early Volume Plays 02.05.10 | 07:02 am
- Netlist, EntreMed: Midday Volume Plays 12.14.09 | 02:12 pm
- ExpressJet, Entremed: Midday Volume Plays 11.16.09 | 02:11 pm
Press Releases for ENMD
- EntreMed Appoints Interim CEO - PR Newswire 04.03.12 | 07:04 am
- EntreMed Initiates Plans For China Office - PR Newswire 03.05.12 | 02:03 pm
- EntreMed Completes Strategic Financing - PR Newswire 02.06.12 | 07:02 am
- Biotech Leaders Wei-Wu He, Ph.D And Tak W. Mak, Ph.D Join EntreMed's Board Of Directors - PR Newswire 02.06.12 | 07:02 am
- EntreMed's ENMD-2076 Demonstrates Promising Activity In A Phase 2 Study In Platinum-Resistant Ovarian Cancer Patients - PR Newswire 10.03.11 | 07:10 am
- EntreMed Enters Into $7.5 Million Equity Facility And Initiates $1.1 Million Drawdown - PR Newswire 06.28.11 | 05:06 pm
- Selected Value Therapeutics Exercises Right To Develop And Commercialize Enmd-2076 In China - PR Newswire 06.07.11 | 11:06 am
- EntreMed's ENMD-2076 Demonstrates Clinical Activity In Recurrent, Platinum-Resistant Ovarian Cancer Patients - PR Newswire 06.03.11 | 03:06 pm
- EntreMed Reports Fourth Quarter And Year-End 2009 Financial Results - PR Newswire 03.29.10 | 04:03 pm
Partner Headlines for ENMD
- China Biotech In Review: GSK Explores All Paths To Increase China Presence - Seeking Alpha 03.11.12 | 07:03 am
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO - Seeking Alpha 09.12.10 | 09:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress - Fox Business 08.16.10 | 12:08 pm
